The American Association of Immunologists (AAI) is pleased to announce the appointment of Anand Balasubramani, PhD, as its inaugural Chief Scientific Programs Officer (CSPO), effective March 25, 2026. This newly established executive role reflects AAI’s commitment to strengthening its scientific programming, expanding its thought leadership, and supporting the rapidly evolving field of immunology.
Dr. Balasubramani brings more than a decade of leadership experience in scientific publishing, program development, and community engagement across nonprofit scientific organizations. Balasubramani joins AAI from the American Society for Microbiology, where he most recently served as Journals Development Editor, leading the launch and growth of high-volume journals and building strategic initiatives and partnerships that advanced the society’s scientific mission. Earlier in his career, as Founding Editor of Science Immunology , he played a lead role in building the journal into a highly respected publication. His scientific background includes research in autoimmunity, cytokine biology, epigenetics, and leukemia.
In his new role as CSPO, Balasubramani will serve as a key member of the AAI senior leadership team, shaping the association’s scientific agenda and overseeing its publications, education, and scientific affairs portfolios. He will lead strategic initiatives, and work closely with AAI staff, Council, and members to ensure that AAI’s scientific programming reflects the breadth and impact of modern immunology—from fundamental discovery to clinical translation.
Loretta Doan, PhD, AAI Chief Executive Officer, welcomed the appointment:
“We are thrilled to welcome Dr. Balasubramani to AAI. His deep roots in the immunology community, exceptional leadership in scientific publishing, and strong strategic vision make him uniquely suited for this role. Anand brings both creativity and experience to scientific program development, and we are confident he will help AAI expand its impact during this exciting period of growth for the field and the organization.”
Dr. Balasubramani said:
“Immunology has evolved into a remarkably diverse discipline spanning discovery science, translational innovation, and therapies that are transforming patient care. I am honored to join AAI at such an exciting time for our field and look forward to working with its members and leaders to build programs that support this expanding community of scientists, clinicians, and healthcare professionals. As immunologists, we will continue our long tradition of advancing discovery and shaping the future of science and medicine.”
AAI created the CSPO role as part of its strategic effort to strengthen its scientific affairs portfolio, expand and modernize its scientific and educational programming, and reinforce its position as a leading voice in the global immunology community. Balasubramani will also play a key role in shaping new initiatives, supporting AAI’s international collaborations, and advancing priorities highlighted in the AAI Strategic Framework .
About the American Association of Immunologists (AAI)
The American Association of Immunologists is one of the world’s largest organizations of immunologists and scientists in related disciplines. AAI members are responsible for many of the most important biomedical discoveries of the past century, including life‑saving cancer immunotherapies, antibody therapies, transplant technologies, and vaccines. AAI supports scientists through knowledge dissemination, advocacy, education, and community building to advance the field of immunology and improve global health.